KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.
A proposal in Washington state would use right-to-try laws to allow terminally ill patients access to psilocybin — the famed magic mushrooms of America’s psychedelic ’60s — to ease depression and anxiety.
Health Canada is investigating the use of non-steroidal anti-inflammatory drugs (NSAIDs) at 20 weeks or later in pregnancy and the rare, but serious, risk of kidney problems in an unborn baby, in response to a Drug Safety Communication recently released by the U.S. Food and Drug Administration (FDA) on this issue.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Health Canada is committed to ensuring that the medical devices available to Canadians meet the necessary safety and effectiveness standards. The Department has contactedcompanies that may be importing or distributing certain respirators, including KN95 respirators, that may not meet expected performance standards in Canada to request that they stop sale and relabel the products as face masks instead of respirators.
In light of the unprecedented demand and urgent need for products that can help fight COVID-19—including household cleaning products, hand soaps and body soaps—as an interim policy, Health Canada is facilitating access to products that may not fully meet current regulatory requirements.
OTTAWA – Health Canada has beenworkingto address the issue of N-nitrosodimethylamine (NDMA) and similar nitrosamine impurities found in certain “sartan” angiotensin receptor blocker (ARB) blood pressure medications since 2018 and, certain ranitidine drugs more recently.
September 6, 2019
OTTAWA – Health Canada is advising Canadians who use vaping products to monitor themselves for symptoms of pulmonary illness (e.g., cough, shortness of breath, chest pain) and to seek medical attention promptly if they have concerns about their health.